Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Monte Rosa Therapeutics Inc (GLUE)

Monte Rosa Therapeutics Inc (GLUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors Quiver Quantitative, Inc. - Fri Dec 13, 4:20PM CST

Monte Rosa Therapeutics appointed Dr. Eric A. Hughes to its Board, enhancing R&D leadership for its molecular glue degrader pipeline.Quiver AI SummaryMonte Rosa Therapeutics, Inc. has announced the appointment...

GLUE : 6.93 (+6.45%)
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors GlobeNewswire - Fri Dec 13, 6:00AM CST

GLUE : 6.93 (+6.45%)
Monte Rosa Therapeutics Announces Licensing Agreement with Novartis to Advance VAV1-Directed Molecular Glue Degrader MRT-6160 Quiver Quantitative, Inc. - Wed Dec 11, 4:19PM CST

Monte Rosa Therapeutics and Novartis entered an exclusive license agreement to develop MRT-6160, targeting immune-mediated conditions.Quiver AI SummaryMonte Rosa Therapeutics, Inc. has finalized an exclusive...

GLUE : 6.93 (+6.45%)
Monte Rosa Therapeutics Announces Promising Preclinical Data for CDK2-Directed Molecular Glue Degrader MRT-9643 in HR-Positive/HER2-Negative Breast Cancer Quiver Quantitative, Inc. - Wed Dec 11, 4:19PM CST

Monte Rosa's MRT-9643 shows promise in treating HR-positive/HER2-negative breast cancer with superior selectivity and reduced toxicities.Quiver AI SummaryMonte Rosa Therapeutics announced promising preclinical...

GLUE : 6.93 (+6.45%)
Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Breast Cancer GlobeNewswire - Wed Dec 11, 6:00AM CST

GLUE : 6.93 (+6.45%)
Monte Rosa Therapeutics Announces Closing of Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders GlobeNewswire - Wed Dec 11, 6:00AM CST

GLUE : 6.93 (+6.45%)
Monte Rosa Therapeutics Announces Positive Interim Results from Phase 1/2 Study of MRT-2359 in MYC-Driven Solid Tumors Quiver Quantitative, Inc. - Thu Dec 5, 4:16PM CST

MRT-2359 shows favorable safety and effective GSPT1 degradation in Phase 1/2 study; Phase 2 dosing schedule recommended.Quiver AI SummaryMonte Rosa Therapeutics, Inc. announced positive interim results...

GLUE : 6.93 (+6.45%)
Monte Rosa Therapeutics Provides Development Progress Update for Ongoing MRT-2359 Phase 1/2 Study in Patients with MYC-driven Solid Tumors GlobeNewswire - Thu Dec 5, 6:00AM CST

GLUE : 6.93 (+6.45%)
Monte Rosa Therapeutics CEO to Participate in Fireside Chat at 36th Annual Piper Sandler Healthcare Conference Quiver Quantitative, Inc. - Tue Nov 26, 4:16PM CST

Monte Rosa Therapeutics' CEO will participate in a fireside chat at the Piper Sandler Healthcare Conference on December 3, 2024.Quiver AI SummaryMonte Rosa Therapeutics, Inc., a clinical-stage biotechnology...

GLUE : 6.93 (+6.45%)
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference GlobeNewswire - Tue Nov 26, 6:00AM CST

GLUE : 6.93 (+6.45%)

Barchart Exclusives

Oracle Stock Is Off Its Highs and Could Be Cheap Here Barchart - 54 minutes ago
Oracle Corp. produced higher revenue in Q2 but lower free cash flow and FCF margins. However, ORCL stock is now off its highs and could be undervalued here. Shorting out-of-the-money puts is one way to play it. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot